Advertisement

Clinical and Pathological Characteristics and Outcomes of Clear Cell Carcinoma of Ovary: A Tertiary Cancer Centre Data

  • Joydeep Ghosh
  • Anik GhoshEmail author
  • Divya Midha
  • Prabir Banerjee
  • Basumita Chakraborti
  • Arunava Roy
  • Shweta Rai
  • Sonia Mathai
  • Sandip Ganguly
  • Deepak Dabkara
  • Bivas Biswas
  • Jaydip Bhaumik
Original Article
  • 1 Downloads

Introduction

Clear cell carcinoma of ovary is a rare disease. Historically, they have been treated in lines of serous ovarian cancer. But available evidence shows different outcomes in these cancers. There is a paucity of data on the outcomes of clear cell carcinoma from India. Here were present the outcomes from a tertiary cancer centre.

Methodology

This was a retrospective study. All patients diagnosed with clear cell carcinoma of the ovary in our centre between 2011 and 2017 were analysed. Only those who had pathological confirmation in our hospital were included. Their clinical and pathological characteristics and outcomes were analysed and compared between subsets using Kaplan–Meier method and log-rank test.

Results

A total of 46 patients were included in the analysis. Median age was 51.6 years (range 29–69 years). The mean baseline CA-125 was 541.52 U/ml (range 6–6137 U/ml). Stage distribution was FIGO stage I, 63%; stage II, 6.5%; stage III, 24%; and stage IV, 6.5%. Median follow-up of the study was 19.5 months (range 2–104 months). The estimated median recurrence-free survival of the overall population was 31 months, and the estimated median overall survival of the overall population was 71 months. For stages I and II and stages III and IV who are clubbed together, the estimated median recurrence-free survival was 79 months and 12 months (P = 0.0003 by Mantel–Cox log-rank test) and overall survival was 14 months and 11 months, respectively (P = 0.007).

Conclusion

Majority of our patient population were at an early stage. The mean CA-125 level was higher compared to Western literature. The outcomes of early stage were much better compared to historic outcomes of serous ovarian cancer; however, the outcomes of advanced stage stay dismal. Prospective studies are needed for generating higher quality of evidence.

Keywords

Clear cell cancer Ovary cancer East India Epithelial ovarian cancer 

Notes

Funding

None.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51(1):15–36.CrossRefGoogle Scholar
  2. 2.
    Crozier MA, Copeland LJ, Silva EG, Gershenson DM, Stringer CA. Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol. 1989;35(2):199–203.CrossRefGoogle Scholar
  3. 3.
    Kennedy AW, Biscotti CV, Hart WR, Webster KD. Ovarian clear cell adenocarcinoma. Gynecol Oncol. 1989;32(3):342–9.CrossRefGoogle Scholar
  4. 4.
    Aure JC, Oslash H, Eg K, Kolstad P. Mesonephroid tumors of the ovary: clinical and histopathologic studies. Obstet Gynecol. 1971;37(6):860.PubMedGoogle Scholar
  5. 5.
    Lim MC, Lee DO, Kang S, Seo S-S, Lee B-Y, Park S-Y. Clinical manifestations in patients with ovarian clear cell carcinoma with or without co-existing endometriosis. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2009;25(7):435–40.CrossRefGoogle Scholar
  6. 6.
    Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88(11):2584–9.CrossRefGoogle Scholar
  7. 7.
    Fujiwara K, Shintani D, Nishikawa T. Clear-cell carcinoma of the ovary. Ann Oncol. 2016;27(suppl_1):i50–2.CrossRefGoogle Scholar
  8. 8.
    Kaur S, Kerkar RA, Maheshwari A, Shylasree TS, Gupta S, Deodhar K. Clinical characteristics with patterns of relapse and survival analysis of ovarian clear cell carcinoma. Indian J Cancer. 2016;53(2):288.CrossRefGoogle Scholar
  9. 9.
    Shu CA, Zhou Q, Jotwani AR, Iasonos A, Leitao MM, Konner JA, et al. Ovarian clear cell carcinoma, outcomes by stage: the MSK experience. Gynecol Oncol. 2015;139(2):236–41.CrossRefGoogle Scholar
  10. 10.
    Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol. 1996;60(3):412–7.CrossRefGoogle Scholar
  11. 11.
    Prendergast EN, Holzapfel M, Mueller JJ, Leitao MM, Gunderson CC, Moore KN, et al. Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma—a multi-institutional cohort. Gynecol Oncol. 2017;144(2):274–8.CrossRefGoogle Scholar
  12. 12.
    Ku F-C, Wu R-C, Yang L-Y, Tang Y-H, Chang W-Y, Yang J-E, et al. Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: results from a single-center Taiwanese study. J Formos Med Assoc. 2018;117(2):117–25.CrossRefGoogle Scholar
  13. 13.
    Bai H, Sha G, Xiao M, Gao H, Cao D, Yang J, et al. The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study. Oncotarget. 2016;7(13):15566–76.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14(10):1020–6.CrossRefGoogle Scholar
  15. 15.
    Iramaneerat K, Rattanatunyong P, Khemapech N, Triratanachat S, Mutirangura A. HERV-K hypomethylation in ovarian clear cell carcinoma is associated with a poor prognosis and platinum resistance. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2011;21(1):51–7.CrossRefGoogle Scholar

Copyright information

© Association of Gynecologic Oncologists of India 2019

Authors and Affiliations

  • Joydeep Ghosh
    • 1
  • Anik Ghosh
    • 2
    Email author
  • Divya Midha
    • 3
  • Prabir Banerjee
    • 1
  • Basumita Chakraborti
    • 2
  • Arunava Roy
    • 2
  • Shweta Rai
    • 2
  • Sonia Mathai
    • 2
  • Sandip Ganguly
    • 1
  • Deepak Dabkara
    • 1
  • Bivas Biswas
    • 1
  • Jaydip Bhaumik
    • 2
  1. 1.Department of Medical OncologyTata Medical CenterKolkataIndia
  2. 2.Department of Gynaecologic OncologyTata Medical CenterKolkataIndia
  3. 3.Department of PathologyTata Medical CenterKolkataIndia

Personalised recommendations